Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for
Alzheimer's disease (AD), have yielded significant insights into the pathogenic mechanism …

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Dysregulation of lipid metabolism has emerged as a central component of many
neurodegenerative diseases. Variants of the lipid transport protein, apolipoprotein E …

The field of Alzheimer's disease (AD) research has grown exponentially over the past few
decades, especially since the isolation and identification of amyloid-β from postmortem …

Abstract The Alzheimer's Association's Research roundtable met in April 2015 to explore the
role of neuroinflammatory mechanisms in the progression of Alzheimer's disease (AD). The …

The heterogeneity and complex nature of Alzheimer's disease (AD) is attributed to several
genetic risk factors and molecular culprits. The slow pace and increasing failure rate of …

Background We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on
brain amyloid measured by amyloid imaging in patients with Alzheimer's disease (AD) in a …

Bexarotene, a retinoid X receptor (RXR) agonist, is approved by FDA to treat cutaneous T-
cell lymphoma. However, it has also demonstrated promising therapeutic potential for …

Alzheimer's disease (AD) is considered as one of the most prevalent neurodegenerative
disorders characterized by progressive loss of mental function and ability to learn. AD is a …

The term oligomeropathies defines the neurodegenerative disorders associated with protein
misfolding, where small soluble aggregates (oligomers 4‐200 KDa) are the cause of …